doi: 10.2147/ppa.s4028.
Therapeutic options in the treatment of benign prostatic hyperplasia
Affiliations
- PMID: 19936164
- PMCID: PMC2778433
- DOI: 10.2147/ppa.s4028
Item in Clipboard
Therapeutic options in the treatment of benign prostatic hyperplasia
Patient Prefer Adherence.
.
Abstract
Current theraputic options for the treatment of symptomatic benign prostatic hyperplasia (BPH) are reviewed. Therapeutic options for mild lower urinary tract symptoms (LUTS), as defined by the American Urological Association, are generally treated medically. Moderate to severe LUTS can be treated medically or with surgical therapy. Current medical and surgical treatments for LUTS secondary to BPH are reviewed and evolving treatments are explored.
Keywords: TURP; benign prostatic hyperplasia; prostatectomy.
Similar articles
-
The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.Prostate. 2021 Sep;81(13):944-955. doi: 10.1002/pros.24190. Epub 2021 Jul 20. Prostate. 2021. PMID: 34288015 Free PMC article.
-
[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6. Prog Urol. 2012. PMID: 23178093 French.
-
Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.Clin Ther. 2006 Jan;28(1):13-25. doi: 10.1016/j.clinthera.2006.01.004. Clin Ther. 2006. PMID: 16490576 Review.
-
Benign prostatic hyperplasia: from bench to clinic.Korean J Urol. 2012 Mar;53(3):139-48. doi: 10.4111/kju.2012.53.3.139. Epub 2012 Mar 19. Korean J Urol. 2012. PMID: 22468207 Free PMC article.
-
Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.Cochrane Database Syst Rev. 2019 May 25;5(5):CD012832. doi: 10.1002/14651858.CD012832.pub2. Cochrane Database Syst Rev. 2019. PMID: 31128077 Free PMC article.
Cited by
-
Successful treatment of complicated benign prostatic hyperplasia in a diabetic patient with water vapor thermal therapy and urethral stenting.Urol Case Rep. 2019 May 22;26:100921. doi: 10.1016/j.eucr.2019.100921. eCollection 2019 Sep. Urol Case Rep. 2019. PMID: 31467853 Free PMC article.
-
Cucurbitacin B Inhibits the Proliferation of WPMY-1 Cells and HPRF Cells via the p53/MDM2 Axis.Int J Mol Sci. 2024 Aug 28;25(17):9333. doi: 10.3390/ijms25179333. Int J Mol Sci. 2024. PMID: 39273281 Free PMC article.
-
The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia by primary care family physicians in Portugal.Clin Drug Investig. 2015 Feb;35 Suppl 1:19-27. doi: 10.1007/s40261-014-0256-4. Clin Drug Investig. 2015. PMID: 25708607
References
-
- Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–479. - PubMed
-
- Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell’s Urology. Philadelphia (PA): Saunders; 2002. pp. 1297–1336.
-
- McConnell MD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338:557–563. - PubMed
-
- McConnell JD, Roehrborn CG, Bautista AM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2385–2396. - PubMed
-
- McConnell JD. Prostatic growth: New insights into hormonal regulation. Br J Urol. 1995;76(Suppl 1):5–10. - PubMed
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
